The global market for human antifungal therapeutics reached nearly $11.6 billion in 2012 and $11.8 billion in 2013. This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2% over the five-year period from 2013 to 2018.
The goal of BCC Research in conducting this study was to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 to 2018. This report covers approved human therapeutics, with a heavy focus on therapeutics in early development. These new molecular and biological entities are from traditional pharmaceutical sources, naturally derived synthetic chemicals and biological sources as well as the "herbal natural folk medicine" marketplace. If an approved or well-known medicine is being studied in combination with another molecular entity, it is considered a new therapy and often has been included for review. New drug and patent applications are presented as the study focuses on new methods of drug administration, drug clinical trials, and discovery and development.
It should be noted that there is a strong emphasis on early research due to the critical need for new and more effective medicines; hence, BCC Research is including a section of medicines intended for human utilization that are in clinical testing as well as information on new and novel in vitro therapies. Greater than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast. We are limiting this research to therapies that depict a positive result or that represent a very rare and novel approach worthy of further review from R&D groups.
Our key objective in this report is to present an in-depth analysis of the current human antifungal market and to explore its future direction. In the last five years there has been a decrease in the number of patent applications filed in this area. Between 1990 and 1999 there were six U.S. patents granted-evidence of the evolution of drug resistance and an increasing mortality rate.,
Fungi are highly resistant microbiological eukaryotic microorganisms. In other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development. The therapies are designed to eradicate these fungi through the various antifungal mechanisms of action, such as disrupting reproductive capabilities, destroying cell walls or modifying fungal DNA and cell functioning. It is a given fact that infestations in humans, animals, plants and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. That being the case, BCC Research was particularly interested in examining the antifungal market growth of developing products depicting efficacy. We are including data regarding the market shift for those products that are now relegated to over-the-counter (OTC) status that previously had only been provided by prescription; moreover, we will identify new antifungal research, development, new drug applications and novel approaches to the market.
Previously, BCC Research examined the antifungal market in its 2003 report, PHM029A The Market for Antifungal Drugs, in PHM029B Global Markets for Antifungal Agents and in PHM029C Antifungal Drugs: Technologies and Global Markets. Due to the rapidly changing market, BCC Research chose to reexamine the marketplace through another analysis and project its new growth potential. Additionally, PHM029A focused only on human fungal diseases and associated antifungals; PHM029B incorporated the marketplace for antifungals in the veterinary, agricultural and environmental industries; and PHM029C and PHM029D focused on human therapeutics with an intensive focus on human therapeutics in the developmental pipeline. PHM029E is an update of PHM029D.
This report was prepared as a study of the global antifungal marketplace based on fungal infections and infestations with a focus on human therapeutics. Information is presented on the antifungal industry in general, specific pharmaceuticals and chemical agents, new technology within the market, new and novel drug applications and market-related issues. In many cases actual revenue is given for the period of 2012 and 2013, with projections of trends and compound annual growth rates (CAGRs) 2013 through 2018.
This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company directors and marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, product managers and representatives, and all manner of institutional directors ranging from nursing homes and schools to long-term-care facilities both public and private. It will also be of interest to biologists and those interested in the field of mycology.
This study examines human applications both currently marketed and in the development of antifungal technologies. In an extensive analysis, BCC Research examines each market segment, presents its current market status and offers various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2012 to 2013, with estimates for 2018, including CAGR as a percentage.
Through an extensive industry survey inclusive of online database searches of industry-specific data sources coupled with financial, trade, government and marketing database sources as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies and academic experts, BCC Research was able to compile data to present our analysis of the antifungal market by market segment.
Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources.
Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for over 22 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology and is currently working on her Ph.D.